Fisher Biosciences strengthens its reagent portfolio through acquisition of BioImage
Fisher Biosciences has acquired BioImage to expand its offering in high content screening and analysis reagent technologies. BioImage complements Fisher Biosciences' existing Cellomics business. The Cellomics platform includes automated imaging instrumentation, BioApplication image analysis software, High Content informatics software and reagent kits. The entire Cellomics product portfolio is fully integrated to improve the quality and productivity of high content cellbased assays. BioImage is a leader in the field of High Content Pathway analysis, providing the life-science market with products, services and licenses that are based on its Redistribution® technology. Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.

Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.